Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 185

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 185
---
 |

| ● | all of our directors and       
 executive officers as a group. |

The beneficial ownership
of our Ordinary Shares is determined in accordance with the rules of the SEC and generally includes any shares over which a person exercises
sole or shared voting or investment power, or the right to receive the economic benefit of ownership. For purposes of the table below,
we deem Ordinary Shares issuable pursuant to options or warrants that are currently exercisable or exercisable within 60 days of the
date of this registration statement to be outstanding and to be beneficially owned by the person holding the options for the purposes
of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage
ownership of any other person. Percentage of shares beneficially owned before this offering is based on 1,571,752 Ordinary Shares issued
and outstanding as of January 24, 2025. The number of Ordinary Shares deemed issued and outstanding after this offering is based on
Ordinary Shares offered hereby but assumes no exercise of the Representative’s over-allotment option.

As of January 24, 2025,
and based on their reported registered office, none of our shareholders were U.S. persons. We have also set forth below information known
to us regarding any significant change in the percentage ownership of our Ordinary Shares by any major shareholders during the past three
years. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners
of the Ordinary Shares listed below have sole investment and voting power with respect to such shares.

Following the closing of
this offering, all of our shareholders, including the shareholders listed below, will have the same voting rights attached to their Ordinary
Shares, and neither our principal shareholders nor our directors and executive officers will have different or special voting rights
with respect to their Ordinary Shares. See “Description of Share Capital—Voting Rights.” A description of any material
relationship that our principal shareholders have had with us or any of our predecessors or affiliates within the past three years is
included under “Certain Relationships and Related Party Transactions.”

Unless otherwise noted below,
the address of each shareholder, director and executive officer is c/o Regentis Biomaterials Ltd., 60 Medinat Hayehudim Street, Herzliya
4676652, Israel.

|                                                             |     | Ordinary     
 Shares       |         |     | Percentage of      
 Ordinary Shares    
 beneficially owned |      |   |     |          |